Literature DB >> 30567283

Citrobacter freundii sepsis in an immunosuppressed patient with pemphigus vulgaris.

Martina Ferranti1, Giulia Tadiotto Cicogna1, Andrea Sattin2, Mauro Alaibac1.   

Abstract

Pemphigus vulgaris is an autoimmune bullous disease that involves the skin and mucous membranes. Current therapies aim to decrease antibody production by means of the use of systemic corticosteroids, immunosuppressive agents and, recently, rituximab, an anti-CD20 monoclonal antibody. However, the chronic immune suppression could entail complications, like infections and secondary malignancies. We describe a case of a patient with pemphigus who developed a sepsis due to Citrobacter freundii infection. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dermatology; infections

Mesh:

Substances:

Year:  2018        PMID: 30567283      PMCID: PMC6301621          DOI: 10.1136/bcr-2018-227091

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Spontaneous Citrobacter freundii infection in an immunocompetent patient.

Authors:  Jason G Whalen; Thaddeus W Mully; Joseph C English
Journal:  Arch Dermatol       Date:  2007-01

3.  Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes.

Authors:  Li-Hsiang Liu; Nai-Yu Wang; Alice Ying-Jung Wu; Chih-Chen Lin; Chun-Ming Lee; Chang-Pan Liu
Journal:  J Microbiol Immunol Infect       Date:  2017-06-22       Impact factor: 4.399

4.  Persistent B Lymphocyte Depletion After an Ultralow Dose of Rituximab for Pemphigus Vulgaris.

Authors:  A Lazzarotto; M Ferranti; A Meneguzzo; G Sacco; M Alaibac
Journal:  J Investig Allergol Clin Immunol       Date:  2018-10       Impact factor: 4.333

5.  Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus.

Authors:  D F Murrell; E Sprecher
Journal:  Br J Dermatol       Date:  2017-11       Impact factor: 9.302

6.  Bacteremia due to Citrobacter braakii: A case report and literature review.

Authors:  Jun Hirai; Kohei Uechi; Mao Hagihara; Daisuke Sakanashi; Takeshi Kinjo; Shusaku Haranaga; Jiro Fujita
Journal:  J Infect Chemother       Date:  2016-08-21       Impact factor: 2.211

7.  Rituximab in pemphigus.

Authors:  Vivien Hebert; Pascal Joly
Journal:  Immunotherapy       Date:  2017-10-24       Impact factor: 4.196

8.  Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.

Authors:  Christian Schoergenhofer; Michael Schwameis; Christa Firbas; Johann Bartko; Ulla Derhaschnig; Robert M Mader; Raute Sunder Plaßmann; Petra Jilma-Stohlawetz; Kalpna Desai; Priya Misra; Ulrich Jäger; Bernd Jilma
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

Review 9.  Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.

Authors:  Pashtoon M Kasi; Hussein A Tawbi; Chester V Oddis; Hrishikesh S Kulkarni
Journal:  Crit Care       Date:  2012-08-31       Impact factor: 9.097

10.  Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.

Authors:  Mauro Alaibac
Journal:  Front Immunol       Date:  2018-04-18       Impact factor: 7.561

View more
  1 in total

Review 1.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.